Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1b Infection with Compensated Liver Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2020
Price :
$35
*
At a glance
- Drugs AZD 7295 (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Arrow Therapeutics
- 08 Aug 2020 This trial has been completed in Slovakia , according to European Clinical Trials Database.
- 09 Jun 2011 New trial record